Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

CompletedOBSERVATIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
LeukemiaLymphomaTumor Lysis SyndromeHyperuricemia
Interventions
DRUG

Rasburicase

Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.

Trial Locations (11)

10032

Columbia University Medical Center, New York

38105

St.Jude Children's Research Hospital, Memphis

46260

Peyton Manning Children's Hospital at St. Vincent, Indianapolis

48201

Children's Hospital Michigan, Detroit

76104

Cook Children's Medical Center, Fort Worth

77030

MD Anderson Cancer Center, Houston

92123

Rady Children's Hospital, San Diego

94304

Stanford University, Palo Alto

02115-6084

Dana-Farber Cancer Institute, Boston

02903

Rhode Island Hospital, Providence

53226-4801

Mid-West Children's Cancer Center, Milwaukee

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

St. Jude Children's Research Hospital

OTHER